Last reviewed · How we verify
Placebo ELLIPTA inhaler — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo ELLIPTA inhaler (Placebo ELLIPTA inhaler) — GlaxoSmithKline. The Placebo ELLIPTA inhaler delivers no active pharmaceutical ingredient, serving as an inert control device in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo ELLIPTA inhaler TARGET | Placebo ELLIPTA inhaler | GlaxoSmithKline | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo ELLIPTA inhaler CI watch — RSS
- Placebo ELLIPTA inhaler CI watch — Atom
- Placebo ELLIPTA inhaler CI watch — JSON
- Placebo ELLIPTA inhaler alone — RSS
Cite this brief
Drug Landscape (2026). Placebo ELLIPTA inhaler — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-ellipta-inhaler. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab